Kathmere Capital Management LLC Sells 63 Shares of Amgen Inc. (NASDAQ:AMGN)

Kathmere Capital Management LLC reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 3.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,833 shares of the medical research company’s stock after selling 63 shares during the period. Kathmere Capital Management LLC’s holdings in Amgen were worth $390,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Regency Capital Management Inc. DE bought a new stake in shares of Amgen during the first quarter worth about $27,000. Maverick Capital Ltd. bought a new stake in shares of Amgen during the first quarter worth about $27,000. KB Financial Partners LLC bought a new stake in shares of Amgen during the first quarter worth about $35,000. Itau Unibanco Holding S.A. bought a new stake in shares of Amgen during the second quarter worth about $39,000. Finally, Lumature Wealth Partners LLC increased its position in shares of Amgen by 82.3% during the second quarter. Lumature Wealth Partners LLC now owns 175 shares of the medical research company’s stock worth $43,000 after acquiring an additional 79 shares in the last quarter. 74.95% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently commented on AMGN shares. Mizuho decreased their target price on shares of Amgen from $222.00 to $194.00 and set a “neutral” rating for the company in a research report on Monday. SVB Leerink reduced their price objective on shares of Amgen from $234.00 to $216.00 and set a “market perform” rating for the company in a research report on Wednesday, November 3rd. Barclays reduced their price objective on shares of Amgen from $230.00 to $228.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 3rd. Royal Bank of Canada reduced their price objective on shares of Amgen from $217.00 to $216.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 3rd. Finally, Morgan Stanley reduced their price objective on shares of Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 12th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $235.50.

AMGN stock traded down $0.56 during midday trading on Thursday, reaching $203.97. 1,699,089 shares of the company’s stock traded hands, compared to its average volume of 2,617,473. The firm has a market capitalization of $114.89 billion, a PE ratio of 21.01, a price-to-earnings-growth ratio of 1.47 and a beta of 0.61. The company has a 50-day moving average price of $209.99 and a two-hundred day moving average price of $227.76. Amgen Inc. has a 52 week low of $200.47 and a 52 week high of $276.69. The company has a debt-to-equity ratio of 4.05, a quick ratio of 1.36 and a current ratio of 1.64.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 2nd. The medical research company reported $4.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.22 by $0.45. Amgen had a return on equity of 108.67% and a net margin of 21.77%. During the same period in the previous year, the firm earned $4.37 earnings per share. As a group, analysts predict that Amgen Inc. will post 16.83 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 8th. Stockholders of record on Tuesday, November 16th will be given a $1.76 dividend. This represents a $7.04 annualized dividend and a dividend yield of 3.45%. The ex-dividend date of this dividend is Monday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 72.50%.

Amgen Company Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Featured Story: Beige Book

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.